Search
Displaying 471–480 of 691 for “retinal diseases”
-
Foundation Chairman, Gordon Gund, Interviewed on Forbes.com
Beacon StoriesThe driving force behind the Foundation’s considerable advances covers those, as well as other compelling subjects, during a 27-minute Q&A.
-
Beacon Stories
Brooke James has had more than a glimpse of what it means to be blind in certain parts of the world. And she can assure you, it’s scary.
-
ProQR Announces Virtual Presentations at Scientific Conferences
ResourceProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual presentations at the Ophthalmology Futures Retina Forum, European Society of Retina Specialists (Euretina) congress and the Annual Meeting of the American Academy of Optometry (AAOpt).
-
Foundation Hosts Workshop on USH1B Research and Therapy Development
Research NewsEmerging dual-vector gene therapies to address current cargo-size limitations were highlighted during the meeting.
-
FFB-Funded Scientists Report on Nine Promising Translational Research Efforts
Research NewsThe Foundation Fighting Blindness has taken the translational challenge head on by investing more than $75 million in therapy-development projects with strong clinical-trial potential through its Translational Research Acceleration Program (TRAP), which includes Gund-Harrington Scholar Awards.
-
The Importance of Stem Cells (a guest post from Dr. David Gamm)
Research NewsDr. David Gamm on the potential of stem cell research to benefit patients with retinal degenerations.
-
Watch Mike’s powerful story and see how your donation drives research toward treatments and cures for retinitis pigmentosa and blinding diseases. Donate today.
-
Nacuity’s Antioxidative Therapy NACA Performs Encouragingly in Phase 1/2 Clinical Trial
Research NewsNACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.
-
Eye on the Cure Podcast | Episode 59: Dr. Robert MacLaren
Eye on the CureDr. Robert MacLaren, a world-renowned retinal surgeon, clinical trial investigator, and research lab leader at the University of Oxford, talks to host Ben Shaberman about the successes and challenges in retinal gene therapy development and clinical trials, as well as advances in robotics for improving retinal surgery outcomes.
-
First Patient Receives AON Therapy for LCA10 in ProQR’s Phase 2/3 Clinical Trial
Research NewsThe treatment, formerly known as QR-110, is designed for people with the retinal disease Leber congenital amaurosis 10
%20(1).png)
